Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Repligen Is Ready to Rebound

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (NASDAQ: RGEN  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Repligen and see what CAPS investors are saying about the stock right now.

Repligen facts

Headquarters (founded)

Waltham, Mass. (1981)

Market Cap

$240.2 million



Trailing-12-Month Revenue

$65.9 million


CEO Dr. Walter Herlihy
CFO Jonathan Lieber

Trailing-12-Month Return on Equity



$47.9 million / $0


Bio-Rad Laboratories
Life Technologies

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 333 members who have rated Repligen believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, succinctly summed up the Repligen bull case for our community:

I missed the bump in Repligen's share price in the spring because I set an outperform threshold of 6 that never quite clicked. The stock has been pulling back over the last month but I still like the growing bioprocessing revenues, courtesy of the excellent acquisition of Novozymes Biopharma Sweden AB in 2011. Repligen still has to outgrow a well-deserved reputation for futility but if they can successfully transition from drug development into products and services there's still a lot of potential for share price appreciation.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, Repligen may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2495281, ~/Articles/ArticleHandler.aspx, 9/26/2016 11:37:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,139.10 -122.35 -0.67%
S&P 500 2,150.17 -14.52 -0.67%
NASD 5,269.91 -35.84 -0.68%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 11:21 AM
RGEN $30.81 Down -1.30 -4.05%
Repligen CAPS Rating: ***
BIO $160.84 Down -0.50 -0.31%
Bio-Rad Laboratori… CAPS Rating: *****
LIFE.DL $0.00 Down +0.00 +0.00%
Life Technologies… CAPS Rating: ***